hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo’ Khan talked with Proactive's Stephen Gunnion about the company securing a landmark contract to deliver the world’s first pivotal Phase III human challenge trial for ILiAD’s whooping cough vaccine candidate.
Khan explained that the agreement marks a major milestone for hVIVO, representing the largest contract in the company’s history and involving the highest number of clinical participants it has ever managed. He highlighted the broader implications for patients, noting that human challenge trials can significantly accelerate the path to market for new treatments.
“This has three major impacts,” Khan said, pointing to faster patient access, a transformative contract for hVIVO PLC, and a precedent-setting moment for the wider clinical trial industry.
The study will use a human challenge model to assess vaccine efficacy in a controlled environment, addressing the unpredictability of whooping cough infection rates in traditional trials. Khan noted that regulators, including the FDA, MHRA and EMA, have aligned on the approach, enabling faster and more cost-effective development.
He also emphasised hVIVO’s unique positioning in the sector, stating, “We are the world leader when it comes to human challenge trials,” citing its experience conducting over 50 trials and inoculating more than 5,000 participants.
The trial is expected to begin this year, with revenue contributions forecast across 2026 and 2027, enhancing both short- and mid-term visibility for the company.
For more videos like this, visit Proactive’s YouTube channel, give this video a like, subscribe to the channel and enable notifications for future content.
#hVIVO #Biotech #ClinicalTrials #VaccineDevelopment #WhoopingCough #Phase3Trial #HumanChallengeTrial #ILiAD #PharmaNews #HealthcareInnovation #BiotechInvesting #LifeSciences
